GRI Bio (GRI) Common Equity (2020 - 2025)
GRI Bio (GRI) posted quarterly Common Equity of $2.0 million for Q3 2025, down 45.55% year-over-year from $3.7 million in Q3 2024, and down 40.01% quarter-over-quarter from $3.3 million in Q2 2025.
GRI Bio (GRI) Common Equity (2020 - 2025) Analysis & Trends
GRI Bio's Common Equity history runs 6 years deep, the most recent figure standing at $2.0 million for Q3 2025.
- In Q3 2025, Common Equity fell 45.55% year-over-year to $2.0 million; the TTM figure through Sep 2025 stood at $2.0 million (down 45.55% YoY), while the FY2024 annual figure was $4.0 million, up 1456.76% from the prior year.
- Common Equity for Q3 2025 stood at $2.0 million, down from $3.3 million in the prior quarter.
- The five-year high for Common Equity was $12.0 million in Q1 2021, with the low at -$5.7 million in Q3 2022.
- The 5-year median for Common Equity is $2.2 million (2023), against an average of $1.7 million.
- Peak annual rise in Common Equity reached 36470.83% in 2021, while the deepest fall reached 233.43% in 2021.
- GRI Bio's Common Equity stood at -$4.8 million in 2021, then soared by 66.48% to -$1.6 million in 2022, then surged by 115.94% to $259000.0 in 2023, then soared by 1456.76% to $4.0 million in 2024, then sank by 50.57% to $2.0 million in 2025.
- Business Quant data shows GRI's Common Equity at $2.0 million in Q3 2025, $3.3 million in Q2 2025, and $1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | 10.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 3.32 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 4.72 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 259,000.00 |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | -3.23 Mn |
| Dec 31, 2022 | -1.63 Mn |
| Sep 30, 2022 | -5.71 Mn |
| Jun 30, 2022 | -5.45 Mn |
| Mar 31, 2022 | -5.15 Mn |
| Dec 31, 2021 | -4.85 Mn |
| Sep 30, 2021 | 8.73 Mn |
| Jun 30, 2021 | 9.85 Mn |
| Mar 31, 2021 | 12.03 Mn |
| Dec 31, 2020 | -1.45 Mn |